- Home
- GAIN vs FDMT Comparison
GAIN vs FDMT Comparison
Compare GAIN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAIN | FDMT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.3M | 515.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GAIN | FDMT |
|---|---|---|
| Price | $15.15 | $9.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $14.75 | ★ $31.71 |
| AVG Volume (30 Days) | 331.5K | ★ 755.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.99% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.32 | $70.28 |
| P/E Ratio | $4.38 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $13.14 | $2.89 |
| 52 Week High | $15.25 | $12.34 |
Technical Indicators
Market Signals| Indicator | GAIN | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 68.33 | 52.29 |
| Support Level | $13.69 | $8.41 |
| Resistance Level | N/A | $10.19 |
| Average True Range (ATR) | 0.31 | 0.69 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 96.42 | 49.59 |
Price Performance
Historical ComparisonAbout GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).